Humana Inc. with ticker code (HUM) have now 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 667 and 550 and has a mean target at $602.19. Given that the stocks previous close was at $500.87 this now indicates there is a potential upside of 20.2%. The 50 day moving average now sits at $494.99 and the 200 day MA is $497.46. The company has a market capitalization of $62,329m. Find out more information at: https://www.humana.com
The potential market cap would be $74,937m based on the market consensus.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
The company has a dividend yield of 0.72% with the ex dividend date set at 30-3-2023 (DMY).
Other points of data to note are a P/E ratio of 22.37, revenue per share of 734.62 and a 6.11% return on assets.
